OmniAb Q3 2026 net loss narrows to $15.73 million; revenue rises 78% to $3.99 million
LLY•OmniAb’s third-quarter 2026 net loss narrowed to $15.73 million, while revenue rose 78% to $3.99 million. The company raised its full-year revenue guidance to $35 million–$39 million and announced an Eli Lilly collaboration with eligibility for up to $370 million in milestone payments and tiered royalties.
1. Quarterly results
OmniAb’s third-quarter 2026 net loss narrowed year over year to $15.73 million. Revenue climbed 78% to $3.99 million, driven primarily by higher service and xPloration revenue.
2. Guidance and collaboration
OmniAb raised its full-year 2026 revenue guidance to $35 million–$39 million from $32 million–$36 million previously. A new ion channel collaboration with Eli Lilly includes eligibility for up to $370 million in milestone payments and tiered royalties.
